| The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease P Huot, TH Johnston, JB Koprich, SH Fox, JM Brotchie Pharmacological reviews 65 (1), 171-222, 2013 | 383 | 2013 |
| Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic M Sharifian-Dorche, P Huot, M Osherov, D Wen, A Saveriano, ... Journal of the neurological sciences 417, 117085, 2020 | 280 | 2020 |
| The serotonergic system in Parkinson's disease P Huot, SH Fox, JM Brotchie Progress in neurobiology 95 (2), 163-212, 2011 | 226 | 2011 |
| Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations P Huot, TH Johnston, T Darr, LN Hazrati, NP Visanji, D Pires, JM Brotchie, ... Movement disorders 25 (10), 1399-1408, 2010 | 176 | 2010 |
| The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea P Huot, M Lévesque, A Parent Brain 130 (1), 222-232, 2007 | 170 | 2007 |
| Dopaminergic neurons intrinsic to the striatum P Huot, A Parent Journal of neurochemistry 101 (6), 1441-1447, 2007 | 162 | 2007 |
| Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein JB Koprich, TH Johnston, P Huot, MG Reyes, M Espinosa, JM Brotchie PloS one 6 (3), e17698, 2011 | 123 | 2011 |
| The serotonergic system in motor and non-motor manifestations of Parkinson’s disease P Huot, SH Fox Experimental brain research 230 (4), 463-476, 2013 | 102 | 2013 |
| Characterization of 3, 4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA … P Huot, TH Johnston, KD Lewis, JB Koprich, MG Reyes, SH Fox, ... Journal of Neuroscience 31 (19), 7190-7198, 2011 | 86 | 2011 |
| Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson’s disease SH Fox, N Visanji, G Reyes, P Huot, J Gomez-Ramirez, T Johnston, ... Canadian journal of neurological sciences 37 (1), 86-95, 2010 | 68 | 2010 |
| Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease C Tissot, A L. Benedet, J Therriault, TA Pascoal, FZ Lussier, ... Alzheimer's Research & Therapy 13, 1-11, 2021 | 58 | 2021 |
| 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA P Huot, TH Johnston, L Winkelmolen, SH Fox, JM Brotchie Neurobiology of aging 33 (1), 194. e5-194. e15, 2012 | 55 | 2012 |
| UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP … P Huot, TH Johnston, KD Lewis, JB Koprich, MG Reyes, SH Fox, ... Neuropharmacology 82, 76-87, 2014 | 52 | 2014 |
| TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque TH Johnston, P Huot, SH Fox, JB Koprich, KT Szeliga, JW James, ... Neuropharmacology 73, 337-347, 2013 | 50 | 2013 |
| L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease P Huot, TH Johnston, JB Koprich, SH Fox, JM Brotchie Neuropharmacology 63 (5), 829-836, 2012 | 50 | 2012 |
| Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque P Huot, TH Johnston, JB Koprich, L Winkelmolen, SH Fox, JM Brotchie Neurobiology of aging 33 (1), 207. e9-207. e19, 2012 | 48 | 2012 |
| The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset A Hamadjida, SG Nuara, D Bédard, F Gaudette, F Beaudry, JC Gourdon, ... Neuropharmacology 139, 61-67, 2018 | 47 | 2018 |
| The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset A Hamadjida, SG Nuara, N Veyres, I Frouni, C Kwan, L Sid-Otmane, ... Psychopharmacology 234, 905-911, 2017 | 47 | 2017 |
| L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease P Huot, TH Johnston, JB Koprich, A Aman, SH Fox, JM Brotchie The Journal of pharmacology and experimental therapeutics 342 (2), 576-585, 2012 | 46 | 2012 |
| Fatty acid amide hydrolase (FAAH) inhibition reduces L-3, 4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned non … TH Johnston, P Huot, SH Fox, JD Wakefield, KA Sykes, WP Bartolini, ... The Journal of pharmacology and experimental therapeutics 336 (2), 423-430, 2011 | 45 | 2011 |
